Scribe Therapeutics

Scribe Therapeutics is a biotechnology company dedicated to developing and designing new therapies based on CRISPR. The company's first technology, known as X-Editing (XE) molecules, consists of highly engineered CRISPR enzymes that offer integrated efficacy, specificity, and deliverability compared to currently available CRISPR genome-editing technologies. This represents a long-term engineering approach that aims to establish CRISPR-based therapies as a new standard in clinical care and expand access to breakthrough treatments that can impact the lives of millions.